- Conditions
- Erosive Esophagitis
- Interventions
- Nexium 20mg, Nexium 10mg
- Drug
- Lead sponsor
- AstraZeneca
- Industry
- Eligibility
- 1 Year to 11 Years
- Enrollment
- 53 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2026
- U.S. locations
- 11
- States / cities
- Mobile, Alabama • Sacramento, California • Miami, Florida + 7 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1–15
of 15
matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
- Conditions
- Gastroesophageal Reflux Disease
- Interventions
- Dexlansoprazole
- Drug
- Lead sponsor
- Takeda
- Industry
- Eligibility
- 12 Years to 17 Years
- Enrollment
- 104 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2014
- U.S. locations
- 35
- States / cities
- Huntsville, Alabama • Mobile, Alabama • Phoenix, Arizona + 32 more
- Conditions
- Gastroesophageal Reflux Disease (GERD)
- Interventions
- IW-3718, placebo, Standard-dose PPIs QD
- Drug
- Lead sponsor
- Ironwood Pharmaceuticals, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 495 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2020
- U.S. locations
- 93
- States / cities
- Anniston, Alabama • Mobile, Alabama • Phoenix, Arizona + 81 more
- Conditions
- Gastroesophageal Reflux Disease
- Interventions
- IW-3718, Matching Placebo, PPI
- Drug
- Lead sponsor
- Ironwood Pharmaceuticals, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 282 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2017
- U.S. locations
- 62
- States / cities
- Dothan, Alabama • Phoenix, Arizona • Tucson, Arizona + 54 more
- Conditions
- Dysphagia, Head and Neck Cancer, Mucositis, Xerostomia
- Interventions
- exercise intervention, amifostine trihydrate, therapeutic dietary intervention
- Behavioral · Drug · Procedure
- Lead sponsor
- Vanderbilt-Ingram Cancer Center
- Other
- Eligibility
- 21 Years and older
- Enrollment
- 41 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2006 – 2008
- U.S. locations
- 1
- States / cities
- Nashville, Tennessee
- Conditions
- Gastroesophageal Reflux Disease (GERD)
- Interventions
- Dexlansoprazole
- Drug
- Lead sponsor
- Takeda
- Industry
- Eligibility
- 2 Years to 11 Years
- Enrollment
- 71 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2027
- U.S. locations
- 6
- States / cities
- Mobile, Alabama • San Francisco, California • Atlanta, Georgia + 3 more
- Conditions
- Refractory Gastroesophageal Reflux Disease, Gastroesophageal Reflux Disease
- Interventions
- Fosamprenavir Calcium & Sodium Alginate, Placebo
- Drug · Other
- Lead sponsor
- Medical College of Wisconsin
- Other
- Eligibility
- 18 Years to 64 Years
- Enrollment
- 60 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2028
- U.S. locations
- 1
- States / cities
- Milwaukee, Wisconsin
- Conditions
- Eosinophilic Esophagitis (EoE)
- Interventions
- Oral Budesonide Suspension (OBS), Placebo
- Drug
- Lead sponsor
- Shire
- Industry
- Eligibility
- 11 Years to 55 Years
- Enrollment
- 318 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2019
- U.S. locations
- 77
- States / cities
- Birmingham, Alabama • Phoenix, Arizona • Tucson, Arizona + 64 more
- Conditions
- Gastroesophageal Reflux Disease (GERD)
- Interventions
- IW-3718, placebo, Standard-dose PPIs QD
- Drug
- Lead sponsor
- Ironwood Pharmaceuticals, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 609 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2020
- U.S. locations
- 98
- States / cities
- Birmingham, Alabama • Dothan, Alabama • Peoria, Arizona + 81 more
- Conditions
- Gastroesophageal Reflux
- Interventions
- IW-3718, Matching Placebo
- Drug
- Lead sponsor
- Ironwood Pharmaceuticals, Inc.
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 93 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014
- U.S. locations
- 10
- States / cities
- North Little Rock, Arkansas • Anaheim, California • Monroe, Louisiana + 7 more
- Conditions
- Malignant Neoplasms of Lip Oral Cavity and Pharynx, Oropharyngeal Cancer
- Interventions
- Modified Barium Swallow (MBS), Swallowing Questionnaire, Symptom Questionnaire, Video-Strobe Procedure, MRI Guided Intensity Modulated Radiotherapy (IMRT) Planning, Standard-of-Care Intensity Modulated Radiotherapy (IMRT) Planning, Intensity Modulated Radiotherapy (IMRT)
- Procedure · Behavioral · Radiation
- Lead sponsor
- M.D. Anderson Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 90 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2026
- U.S. locations
- 1
- States / cities
- Houston, Texas
- Conditions
- Dysphagia, Oral Phase, Stroke, Ischemic
- Interventions
- Lingual Endurance Training
- Other
- Lead sponsor
- University of Cincinnati
- Other
- Eligibility
- 21 Years and older
- Enrollment
- 19 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2023
- U.S. locations
- 1
- States / cities
- Cincinnati, Ohio
- Conditions
- Gastroesophageal Reflux Disease, Erosive Esophagitis
- Interventions
- Dexlansoprazole, Placebo
- Drug
- Lead sponsor
- Takeda
- Industry
- Eligibility
- 12 Years to 17 Years
- Enrollment
- 63 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2014
- U.S. locations
- 32
- States / cities
- Huntsville, Alabama • Mobile, Alabama • Phoenix, Arizona + 29 more
- Conditions
- Gastroesophageal Reflux Disease
- Interventions
- Lansoprazole microgranules suspension, Placebo
- Drug
- Lead sponsor
- Takeda
- Industry
- Eligibility
- 1 Month to 11 Months
- Enrollment
- 162 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2006 – 2007
- U.S. locations
- 9
- States / cities
- Tampa, Florida • Park Ridge, Illinois • Shreveport, Louisiana + 6 more
- Conditions
- Dysphagia, Pain, Stage I Oropharyngeal Squamous Cell Carcinoma, Stage II Oropharyngeal Squamous Cell Carcinoma, Stage III Oropharyngeal Squamous Cell Carcinoma
- Interventions
- Dexamethasone, Placebo, Quality-of-Life Assessment, Questionnaire Administration, Transoral Robotic Surgery
- Drug · Other · Procedure
- Lead sponsor
- OHSU Knight Cancer Institute
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 76 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2017
- U.S. locations
- 1
- States / cities
- Portland, Oregon